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Abstract 
Aims: Prevalence and clinical significance of right atrial enlargement has been poorly characterized 
in hypertrophic cardiomyopathy  
Methods: One hundred and sixty consecutively patients with hypertrophic cardiomyopathy 
(35.5±20 years; 64% men) were studied. They underwent clinical examination, standard ECG, M-
mode, 2D and Doppler echocardiography, stress test and ECG Holter monitoring. Major adverse 
cardiac events were considered: 1) cardiac death (sudden death, heart failure death); 2) cardiac 
transplant; 3) resuscitated cardiac arrest or appropriate ICD discharge. Genetic analysis of  8              
sarcomeric genes was performed using Sanger sequencing. 
Results: Right atrial enlargement was observed in 22 patients (14%), associated with left atrial en-
largement in all cases. Patients with right atrial enlargement were likely to have restrictive mitral 
pattern (p<0.001) and had higher NYHA (p<0.001), pro NT BNP (p<0.001), left atrial volume in-
dex (p<0.001), lateral (p=0.04) and septal (p=0.002) E/e’, systolic pulmonary artery pressure 
(p<0.001) and lower ejection fraction (all p<0.001). On cardiopulmonary exercise testing, peak 
VO2 was lower and VE/VCO2 higher in patients with right atrial enlargement (p<0.001).  
During a mean follow-up of 4±2.1 years, 30 MACE in 24 patients (15%) were observed. Cox pro-
portional hazards regression analysis, identified right atrial enlargement as an independent predictor 
of MACE (OR= 2.6; CI 1.5 to 4.6; p=0.001). In patients with right atrial enlargement who were ge-
netically tested, there was a higher prevalence of sarcomeric gene mutations (68%) double muta-
tions (16%), and troponin T mutations (21%). 
Conclusions: RAE is present in a small subset of patients with HCM,  and largely reflects increased 
pulmonary pressures due to severe diastolic and/or systolic LV dysfunction. Patients with RAE had 
a higher prevalence of sarcomeric gene mutations, troponin T mutations, and complex genotypes. In 
conclusion, RAE may serve as a very useful marker of disease progression and adverse outcome in 
patients with sarcomeric HCM. 
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Introduction 
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, affecting ap-
proximately 1:500 subjects in the general population (1-3). The clinical expression of HCM is het-
erogeneous, and the awareness of the diverse disease spectrum and clinical course has expanded 
substantially over the last decade (4-5). Most individuals with HCM remain asymptomatic, but 
someone can experience progressive exercise intolerance and heart failure symptoms, and unex-
pected sudden cardiac death can occur at any age (6-8). 
Left atrial enlargement (LAE)  has been shown to be a sensitive marker of filling pressures and ad-
verse prognosis in HCM (9-10). Right atrial enlargement (RAE) have been less well investigated in 
HCM. In this study, we sought to characterize prevalence, clinical significance and genetic epide-
miology of RAE in HCM. We hypothesized that RAE represent a marker of disease severity, and 
thus measurement of right atrial size by conventional echocardiography may provide additional 
prognostic information in patients with HCM. 
 
Methods 
Patient population 
This is an observational cross-sectional cohort study, including HCM patients seen from 2001 to 
2011. All patients were from southern Italy and were of Caucasian descent. HCM was defined as 
unexplained left ventricular hypertrophy (wall thickness of >15 mm in adults; z-score value>2 in 
children). A previously described, syndromic (n=34), metabolic (n=4), infiltrative (n=2) and neu-
romuscular (n=5) disorders associated with HCM were excluded following a standard protocol us-
ing non invasive, and when necessary, invasive investigations (muscle biopsy, fat/rectal biopsy and 
endomyocardial biopsy) (11). 
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Study protocol 
All patients underwent a complete cardiovascular evaluation, including family and personal history, 
physical examination, blood tests including N-terminal prohormone of brain natriuretic peptide 
(NT-proBNP) measurement, 12-lead electrocardiogram (ECG) at rest, conventional M-mode, two-
dimensional and Doppler echocardiography, 24-hour Holter ECG and treadmill or cardiopulmonary 
exercise testing. New York Heart Association (NYHA) class based on the degree of dyspnoea or 
exercise limitation, was evaluated to define the severity of heart failure. Non sustained ventricular 
tachycardia during 24 hour ambulatory ECG monitoring was defined as three or more consecutive 
ventricular beats at rate of ≥120 beats/min, lasting for < 30 seconds. An abnormal blood pressure 
response during exercise was defined as initial increase in systolic blood pressure (SBP) with a sub-
sequent fall of >20 mmHg compared with the blood pressure value at peak exercise or a continuous 
decrease in SBP throughout the exercise test of >20 mmHg compared with resting blood pressure  
or  an increase of <20 mmHg in SBP from resting state to peak exercise (12).  A clinical evaluation 
including standard ECG and echocardiography was generally repeated every six months. An ECG 
Holter and an exercise test were generally performed at least once a year. Genetic analysis was per-
formed after informed consent, according to the procedure established by the Ethic Committee of 
our institution.  
 
Echocardiographic evaluation 
Left ventricular (LV) end-diastolic and end-systolic diameters and shortening fraction, end-diastolic 
thicknesses of interventricular septum and left ventricular posterior wall, were obtained from M-
mode echocardiograms, according to recommendations of the American Society of Echocardiog-
raphy (13).  
At two-dimensional echocardiography, sites and maximal extent of ventricular hypertrophy were 
assessed in end-diastole by parasternal short axis view. LV end-diastolic and end-systolic volumes 
and ejection fraction (EF) were calculated from apical views, using the biplane method of discs 
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(modified Simpson’s rule). An EF<50% was considered abnormal. Left atrial (LA) volume index 
was measured using the biplane area-length method. The maximal LA area was measured in apical 
4 and 2 chamber views by tracing the endocardial border, excluding the confluence of the pulmo-
nary veins as well as the LA appendage. LA length was measured from the midline of the plane of 
the mitral annulus to the opposite superior aspect of the LA. The measurements were performed at 
end-systole from the frame immediately preceding mitral valve opening. LA volume greater than  
34 ml/m2was consider as LAE (14).   
Right atrium (RA) area was calculated by planimetry (tracing the endocardium, and paying atten-
tion to exclude the possible redundancy of the great vein valves) in the apical four-chamber view at 
the point of tricuspid valve opening, and was corrected for height (RA area index), as previously 
reported (15). RA area greater than 18 cm2 was considered as RAE (16). 
Systolic intraventricular gradients were assessed using continuous wave Doppler. A systolic peak 
gradient greater than 30 mmHg, at rest or after a Valsalva manouver, were considered abnormal. 
LV diastolic function was assessed by pulsed Doppler at the level of mitral tips. Peak flow velocity 
in early diastole and during atrial contraction, and E/A ratio were measured, as well as deceleration 
time of early diastolic flow velocity. The pattern of left ventricular filling was classified as: restric-
tive if deceleration time < 120 ms or E/A ≥ 2 associated with deceleration time ≤ 150 ms; abnormal 
relaxation if E/A < 1 associated with deceleration time ≥220 ms; normal (or ‘‘pseudonormal’’) fill-
ing in presence of intermediate patterns (17). In patients with atrial fibrillation, only E wave and de-
celeration time were measured. Systolic, early diastolic (e’), and late diastolic tissue Doppler ve-
locities were measured at the lateral mitral and septal walls and subsequently averaged over 3 cardi-
ac cycles in accordance with previously reported methods (18). Transmitral E/e’ ratios (lateral, sep-
tal, average) were calculated for each patient. E/e’ average ratio was considered increased if higher 
than 15. 
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Clinical Events 
Sudden cardiac death was defined as unexpected sudden collapse within one hour of onset of symp-
toms occurring in patients who had previously experienced a relatively stable or uneventful clinical 
course. Heart failure-related death was defined as death occurring in the context of cardiac decom-
pensation and progressive disease course one year or more before death.  
End stage evolution was defined as development of hypokinetic LV with an left ventricular EF 
<50%. In patients who had already presented at our center with a dilated and/or hypokinetic left 
ventricle, diagnosis of HCM always included previous echocardiographic documentation of classic 
HCM and family screening.  
Major adverse cardiac events (MACE) were considered: 1) cardiac death (sudden death, death for 
heart failure); 2) cardiac transplant; 3) resuscitated cardiac arrest (“aborted sudden death”) or ap-
propriate implantable cardiac defibrillator discharge.  
Genetic analysis  
All exons, including the splicing sites, and 5’ and 3’ UTR regions of the beta myosin heavy chain, 
myosin binding protein C, troponin T, troponin I, alpha tropomyosin, regulatory myosin light chain, 
essential myosin light chain, alpha-cardiac actin, protein kinase, AMP-activated, gamma 2 and ly-
sosomal-associated membrane protein 2 were amplified by polymerase chain reaction, as previously 
described. Polymerase chain reaction products were then examined for sequence variations by 
Sanger sequencing. Nucleotide positions were numbered on the basis of the cDNA sequence ac-
cording to the den Dunnen and Antonarakis nomenclature (19). When sequence variation was de-
tected, the patient’s available relatives underwent genetic screening.  
Statistical analysis  
Statistical analysis was performed using a commercially available package (SPSS,  version15.0 
2002, Chicago: SPSS Inc.). Data are presented as percentages, or means and standard deviations. 
Categorical variables were compared using the Fisher exact test or the χ2 statistic. Two groups of 
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normally distributed variables were compared using the Student t test, and analysis of variance was 
used to compare more than 2 groups. Skewed data were analyzed using the Mann Whitney U test, 
the Wilcoxon rank-sum test and the Kruskal-Wallis test, as appropriate. Linear regression and lo-
gistic, stepwise, multivariable models were performed to analyze predictors of RAE (baseline) and 
RA remodelling (during follow-up). For the survival analysis, the start of follow-up was defined as 
the first cardiovascular evaluation at Monaldi Hospital. Variables selected by univariate statistic 
(p<0.01) were selected for a multivariable Cox regression as an interactive stepwise backward elim-
ination method, each time excluding the one variable with the highest p-value according to Wald 
statistics. The assumption of linearity was checked graphically by studying the smoothed martingale 
residuals from the null model plotted against the covariate variables. The linearity assumptions 
were satisfied. The Hosmer–Lemeshow goodness-of-fit test was used to check that the model ade-
quately fit the data. In order to decrease the inflation of the Type 1 error rate due to multiple testing, 
the statistical significance was defined as two-sided p-value <0.01.  
 
Results 
Study population  
The study cohort comprised one hundred and sixty consecutive patients. The mean age at the first 
evaluation was 35.5±20 years (age ranging from birth to 74 years); 103 (64%) patients were men. 
Family history of HCM was present in 84 patients (53%), while family history of sudden cardiac 
death in 43 patients (27%). The diagnosis was based on symptoms in 75 patients (47%), incidental 
finding in 57 patients (35.5%) and family screening in 28 patients (17.5%).  
RAE was observed in 22 patients (13.7%), and was always associated with LAE (biatrial enlarge-
ment). Table 1 shows a comparison of clinical characteristics of patients with HCM with (n= 22) 
and without (n=138) RAE. Moderate to severe diastolic dysfunction and elevated non invasive 
wedge/systolic pulmonary pressure were observed in almost all patients with RAE, compared with 
no RAE patients (p<0.0001). Four patients (18%) had an end stage disease (i.e. hypokinetic evolu-
 9 
tion; EF<50%). Two patients had a cardiac arrest (at disease onset or in the first month after the 
first evaluation). A logistic, stepwise forward, multivariate model including all the significant vari-
ables at univariate analysis, demonstrated that systolic pulmonary artery pressure>30mmHg 
(p=0.025; OR 1.1; 95% CI 1-1.2) and NYHA class>2 (p=0.05; OR=3.9; 95% CI 1.5-13) were inde-
pendent predictors of RAE. 
 
Follow-up and cardiac events  
Clinical events are reported in Table 2. During a mean follow-up of 4±2.1 years, a cardioverter                 
defibrillator was implanted in 24 (15%) and an appropriate discharge occurred in 3 patients (1.9%). 
Seventeen patients experienced heart failure episodes requiring hospitalization, including 8 with 
RAE (5 patients with EF<50%) and 9 without RAE (7 with EF<50%). Stroke events were more 
frequent in patients with (14%) than patients without (<1%) RAE. Four patients in the RAE cohort 
(18%) were listed for transplant, 3 of them underwent successful orthotopic heart transplant, one 
patient underwent ventricular assist device implantation. Six patients, in the entire cohort, died. The 
cause of death was sudden in 1 patient in each group (HCM with or without RAE). Two patients, 1 
from each group, died from complications soon after heart transplant surgery. The patient who un-
derwent ventricular assist device implantation, died of multiorgan failure after 1 week. One  patient 
with HCM without RAE died from non-cardiac causes. Cox proportional hazards regression analy-
sis, with clinical and echocardiographic variables significant at chi-square analysis and univariate 
binomial model (including: EF <50%, atrial fibrillation, restrictive filling pattern, septal E/e’>15) 
identified RAE (as a time-dependant covariate) as independent predictor of MACE (OR= 2.6; 95% 
CI 1.5, to 4.6; p=0.001). Figure 1 shows a comparison of survival free of MACE between patients 
with RAE (RAE; n=22; 14%), patients with isolated LAE (n=101; 63%) and patients with no signs 
of atrial enlargement  (n=37; 23%) (p=0.0001). 
 
 10 
Genetic results and genotype-phenotype correlation 
Genetic investigation has been completed for 94 of 160 patients with HCM: sequencing analysis of 
10 genes identified a total of 61 mutations in 52 independent HCM patients (overall prevalence 
55.3%). Of these, 59 (97%) mutations have been previously reported as associated to HCM pheno-
type, whereas 2 (3%) were novel variants.  Novel mutations are absent from any publicly available 
databases (ESP and dbSNP137, that also includes the 1000Genome Project data, MAF = 0) and are 
considered pathogenetic by in silico functional prediction using bioinformatics programs 
(http://genetics.bwh.harvard.edu/pph/; http:// sift.jcvi.org/; http://neurocore. char-
ite.de/MutationTaster, for coding variants; a specific software Alamut 2.0 was used to search for 
splicing prediction). 
When we separated genotyped HCM patients with RAE (n=20) from patients without RAE (n=74) 
prevalence of sarcomeric mutations was significantly higher in the first group (85% vs 50.3%; 
p<0.004, figure 3). Molecular epidemiology, with respect to 8 sarcomeric genes plus LAMP and 
PRKAG2, was different between the two group as regards TNNT2 mutations (20% in HCM with 
RAE vs 3.7% in patients without RAE, p: 0.016). Overall, 8 patients (8.5%) had a complex geno-
type, characterized by double-gene mutation heterozygosis (n=4; 4.2%), compound heterozygosis 
(n=3; 3.2%), and homozygosis (n=1; 1%). Also complex genotypes were more frequent in HCM 
patients with RAE (20% vs 5.3% in patients without RAE, although it is not statistically different -
p: 0.058 - Figure 2). 
 
Discussion 
This study analyzed for the first time prevalence, clinical significance, and genetic background of 
RAE in a relatively large cohort of patients with HCM. The main findings of the study were: 1) the 
occurrence of RAE in a small subgroup (14%) of HCM patients; 2) the association of RAE with 
MACE; 3) a high prevalence of sarcomeric mutations, TNNT2 mutations, and complex genotypes 
in patients with RAE.  
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Clinical Significance of RAE 
HCM is characterized by heterogeneous phenotypic expression. This affects the presence, degree 
and localization of myocardial hypertrophy, disarray, and fibrosis; the presence, severity and site  of 
intracavitary obstruction; the presence and severity of diastolic and systolic dysfunction; and  natu-
ral history and clinical outcome (20).  
Heart failure symptoms in patients with HCM are mainly related to left ventricular outflow tract ob-
struction, diastolic dysfunction (heart  failure with preserved ejection fraction), and systolic dys-
function (heart failure with reduced ejection fraction) (21). Left ventricular outflow tract obstruc-
tion, LAE, restrictive physiology and reduced EF (<50%) are known to be associated with adverse 
prognosis in HCM (22-24). “Restrictive physiology” is generally evaluated by non invasive echo-
cardiographic indices, such as transmitral and pulmonary flow velocities, and by using tissue Dop-
pler measurements such as diastolic mitral annulus velocities (E/e’ ratio). However, these indices 
shows only a modest correlation with the invasive measurement of left atrial and wedge pressure by 
cardiac catheterization, and their reproducibility is low in presence of atrial fibrillation and in the 
late stages of the disease (25). The measurement of right atrial size by conventional echocardiog-
raphy is relatively easy and reproducible, even in presence of atrial fibrillation and in the end stage 
phase of the disease. However, the additional prognostic value of right atrial size measurements has 
not been analyzed, so far. In this study, patients with RAE were more symptomatic, had more se-
vere exercise limitation, greater NT-proBNP elevation, elevated systolic pulmonary artery pressure, 
and presence of advanced diastolic and/or systolic dysfunction. In this study, RAE seems a good 
marker of end-stage progression, and largely reflects increased pulmonary pressures due to severe LV dys-
function (which may be purely diastolic or systo-diastolic). Thus, RAE may serve as a very useful marker of 
disease progression towards the end-stage phase. In clinical practice, RAE is generally considered a sur-
rogate of severe restrictive physiology and pulmonary hypertension. However, a subset of patients 
had only mild diastolic abnormalities, suggesting that RAE may represent a relatively early marker 
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of a “restrictive phenotype”, preceding a clinically evident “restrictive physiology”. Thus, meas-
urement of RA size may be of help to guide clinical management of patients with non obstructive 
HCM, particularly when evaluation of systolic and diastolic function is complicated by atrial fibril-
lation.   
Supportive evidence for this comes from a postmortem study by Melacini et al. looking at HCM pa-
tients who developed severe progressive heart failure. Interestingly, patients with non-obstructive 
HCM and RAE deteriorated to advanced NYHA classes III–IV associated with diastolic dysfunc-
tion or atrial fibrillation, compared to other HCM groups. Pathological examination of gross heart 
specimens showed small ventricular cavities, markedly enlarged atria, only focal scars of myocardi-
al fibrosis, and mild left ventricular hypertrophy (26). 
 
Genetic Epidemiology and Pathogenesis of RAE 
The presence of RAE phenotype was associated with a higher frequency of mutations in sarcomeric 
genes (68% vs. 43%). A higher frequency of double mutations (16% vs 0%) was also observed. Re-
cently, Biagini et al. studied a large cohort of end-stage HCM patients (27) and found complex gen-
otypes with double or triple mutations in 13% compared with 5% of the reference cohort (p=0.01). 
However, as in the present study, the outcome of end stage HCM was independent of genotype. 
There was also a relatively high percentage of troponin T mutations. Of note, three patients with 
troponin T mutations had cardiac arrest (H11, H43, H133), while patient H133 has been listed for 
heart transplant. However, given the relatively small cohort of patients studied, it is was not possi-
ble to analyze a potential correlation between genotype and outcome in this subgroup.  
The mechanism of RAE is unknown. Progressive diastolic dysfunction and atrial fibrillation may 
represent adequate substrates for right atrial remodeling. A progressive “atrial myopathy” has also 
been suggested in patients with HCM (28). A genetic basis of RAE is an attractive hypothesis, alt-
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hough it is likely that the atrial remodelling is a complex phenotype requiring both genetic (i.e. 
double mutations) and non genetic (haemodynamic) effects.  
 
 
Study Limitations 
Although our study population and the number of clinical events is relatively small, this is the first 
study to analyze prevalence and potential clinical impact of RAE in HCM. Recent guidelines rec-
ommend the use of RA volume as the gold standard to measure RA size  (13). This study was con-
ducted before 2015, and RA size was measured as suggested by previous guidelines (16). Only few 
patients underwent cardiac catheterization, with invasive estimation of left ventricular end-diastolic 
pressure and left/right atrial pressure measurements (n=5). However, the correlation between the 
Doppler-derived diastolic parameters (transmitral Doppler flow velocities and mitral annular veloci-
ties) and invasive measurements measurement was behind the scope of the study .  
 
Conclusions 
RAE is present in a small subset of patients with HCM,  and largely reflects increased pulmonary 
pressures due to severe diastolic and/or systolic LV dysfunction. Patients with RAE had a higher 
prevalence of sarcomeric gene mutations, troponin T mutations, and complex genotypes. In conclu-
sion, RAE may serve as a very useful marker of disease progression and adverse outcome in pa-
tients with sarcomeric HCM. 
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Figure Legend 
 
Figure 1: Cumulative risk for adverse outcome in patients with classic HCM, patient with no atrial 
dilation, isolated LAE, and patients with RAE. MACE (major adverse cardiac events) was defined 
as combined end point including death, heart transplant/transplant list, aborted sudden 
death/appropriate ICD discharge.  
 
Figure 2: Distribution of sarcomeric gene mutations in the study population: comparison between 
HCM patients with and without RAE.   
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Table 1. Baseline characteristics of HCM patients with and without RAE at first evaluation.  
 
 RAE  
(n=22) 
No RAE 
(n=138) 
p 
Family history of HCM (n,%) 10 (45%) 75 (54%) 0.44 
Family history of SD (n,%) 7 (32%) 36 (26%) 0.57 
Family history of ES (n,%) 6 (27%) 24 (17%) 0.27 
Family history of RAE (n,%) 5 (23%) 5 (3%) <0.001 
Age at diagnosis (y) 34±19 28±20 0.21 
Age at first evaluation (y) 39±18 35±20 0.41 
BSA (cm2) 1.8±0.3 1.8±0.2 0.77 
NYHA Class 2.5±0.4 1.6±0.7 <0.001 
Syncope (n,%) 5 (23%) 17 (12%) 0.19 
Maximal wall thickness (mm) 19.9±4.5 20±5.8 0.96 
LVEDD (mm) 49±6.7 45±6.6 0.009 
LAVI (ml/m2) 61±27 38±15 <0.001 
RAA (cm2) 37±14 18±2.2 <0.001 
RAAI (cm2/m) 18±9.5 8±1.4 <0.001 
TAPSE 18.3±3.2 19.3±2 0.06 
Moderate/Severe TR 4 (18%) (1%) <0.001 
LVOT (n,%) 6 (27%) 46 (33%) 0.57 
Table
  
EF (%) 51 ± 9 58 ± 7.7 <0.001 
E/A (m/sec) 1.83±0.8 1.31±0.5 0.001 
MFP-Abnormal relaxation (n,%) 4 (18%) 96 (69%) <0.001 
MFP-Pseudonormal (n,%) 12 (54%) 28 (20%) <0.001 
MFP-Restrictive (n,%) 6 (27%) 2 (18%) <0.001 
Septal E/e’ ratio 16.9 ±7.6 12.4±6 0.002 
Lateral E/e’ ratio 11.6± 4.4 9.5± 4.7 0.046 
Average E/e’ ratio 14± 3.7 10.8± 2.5 <0.001 
PAPs (mmHg) 44±13 31±6.6 <0.001 
NT proBNP (pg/ml)* 1609±1035 545±893 <0.001 
VO2 (mg/Kg/min)** 14.8±3.8 19.9±5 <0.001 
VE/VCO2 slope*** 31.9±5.7 27±6.8 <0.001 
Atrial fibrillation (n,%)  11 (50%) 17 (12%) <0.001 
NSVT (n,%) 2 (9%) 5 (4%) 0.24 
Medical treatment (n,%) 21 (95%) 109 (79%) 0.06 
Diuretics (n,%) 12 (55%) 13 (9%) <0.001 
Warfarin (n,%) 9 (41%) 10 (7%) <0.001 
Beta Blockers (n,%)  15 (68%) 80 (58%) 0.36 
  
Calciumantagonists (n,%)  3 (14%) 14 (10%) 0.62 
Surgical Myectomy (n,%) 1 (5%) 5 (4%) 0.83 
ICD implantation (n,%) 1 (5%) 1 (0.7%) / 
Cardiac arrest (n,%) 2 (9%) 0 (0%) / 
Heart failure episodes (n,%)  8 (36%) 6 (4%) <0.001 
 
 
BSA: body surface area; EF: ejection fraction; ES: end stage; HCM: hypertrophic cardiomyopathy; ICD: implantable 
cardioverter defibrillator; LAVI: left atrial volume index; LVEDD: left ventricular end-diastolic diameter; LVOT: left 
ventricular outflow tract obstruction; MFP: mitral filling pattern; NSVT: non-sustained ventricular tachycardia; NYHA: 
Hew York Heart Association; RAA: right atrial area; RAAI: right atrial area index;   SD: sudden death; sPAP: systolic 
pulmonary artery pressure; TAPSE: Tricuspid annular plane systolic excursion; TR: tricuspid regurgitation.  
 
*Available in 128 patients (HCM with BAE,  n=22) 
** Available in 98 patients (HCM with BAE,  n=18) 
*** Available in 89 patients (HCM with BAE,  n=1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2. Cardiac events during follow-up.  
 
 RAE 
(n=22) 
No RAE 
(n=138) 
p 
Surgical Myectomy (n,%) 1 (5%) 5 (4%) 0.83 
Stroke (n,%) 3 (14%) 1 (0.007%) <0.0001 
ICD implantation (n,%) 6 (27.3%) 18 (13%) 0.08 
Heart failure episodes (n,%) 8 (36.3%) 9 (6.5%) <0.0001 
Heart Transplant/VAD (n,%) 4 (18%) 1 (0.7%) <0.0001 
Appropriate ICD discharge 
(n,%) 
1 (4.5%) 2 (1%) / 
Sudden Death (n,%) 1 (4.5%) 1 (0.7%) / 
Cardiac Death (n,%) 2 (9%) 1 (0.7%) / 
Non Cardiac Death (n,%) / 1 (0.7%) / 
 
ICD: implantable cardioverter defibrillator; RAE: right atrial enlargement, VAD: ventricular assist device.  
